Literature DB >> 6931450

Continuous-flow leukapheresis for rapid cytoreduction in leukemia.

T A Lane.   

Abstract

Three patients with leukemia were treated for acute leukostasis using the continuous-flow cell separator. The first patient, treated with a standard procedure sustained only a 14 per cent decrease in leukocyte count even though 50 X 10(10) leukocytes were removed. A more aggressive approach was taken with the second two patients by increasing the rate of leukocyte removal three- to fourfold. In these patients, 100 to 230 X 10(10) leukocytes were removed and prepheresis counts dropped by 48 to 85 per cent. Both had satisfactory clinical response to pheresis. The data suggest that an aggressive pheresis can effectively treat symptoms associated with acute leukostasis. Finally, the continuous-flow cell separator has distinct advantages over the discontinuous-flow separator in patients with small blood volumes.

Entities:  

Mesh:

Year:  1980        PMID: 6931450     DOI: 10.1046/j.1537-2995.1980.20480260280.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  4 in total

Review 1.  Common emergencies in cancer medicine: hematologic and gastrointestinal syndromes.

Authors:  C R Thomas; I K Carter; W T Leslie; F Sutton
Journal:  J Natl Med Assoc       Date:  1992-02       Impact factor: 1.798

2.  Severe hyperleukocytosis and multifocal intracranial haemorrhage: not always a fatal outcome.

Authors:  Antonio Ruggiero; G Attinà; M Piastra; P Maurizi; S Mastrangelo; D Pietrini; R Riccardi
Journal:  Int J Hematol       Date:  2009-05-23       Impact factor: 2.490

3.  Acute Myeloid Leukemia Complicated by Hyperleukocytosis and Leukostasis in the Emergency Department.

Authors:  Ryan T Ngo; Amanda L Webb McAdams; Anthony Furiato
Journal:  Cureus       Date:  2021-06-02

4.  [The patient with leukemia in the intensive care unit].

Authors:  S Zierhut; A Reichle
Journal:  Intensivmed Notfallmed       Date:  2007-05-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.